Blood test distinguishes neuroendocrine subtype of advanced prostate cancer
Like a criminal entering a witness protection program, cancer cells can shed their past and take on a new identity. Detecting such an identity-switch is particularly challenging when metastatic castration-resistant prostate cancer (CRPC) advances from adenocarcinoma to neuroendocrine prostate cancer (NEPC), a very difficult cancer to treat. Now, however, researchers at Dana-Farber Cancer Institute and … Read more